The following telephone arguments will be available to the
public live. Access information will be available by 9 AM ET
each day of argument at:
http://www.cafc.uscourts.gov/public-access-arguments.
Wednesday, March 9, 2022
Sanofi-Aventis Deutschland GmbH v. Mylan
Pharmaceuticals Inc., No. 21-1981
Mylan petitioned for inter partes review (“IPR”) of
Sanofi's U.S. Patent No. RE47,614, challenging the claims as
obvious over, among others, a secondary prior art reference de
Gennes. In concluding the challenged claims were obvious, the Board
determined de Gennes is analogous art in this particular case to
the '614 patent under the reasonable pertinence prong of the
test for analogous art in this case.